Haptoglobin, Phenotype 1-1, Low Endotoxin Level [9087-69-8]

Athens Research

Haptoglobin, Phenotype 1-1, Low Endotoxin Level [9087-69-8]

9

Animal Studies,Cell Based Assays, ELISA, Protein Chemistry, Inflammation, Sickle Cell Anemia, Glycosylation, Stroke, Central Nervous System Injury, Diabetes, Cardiovascular Disease, In Vitro Diagnostic, Iron Metabolism, Cancer

Research Use Only

≥ 95% by SDS-PAGE, no visible alpha-2 light chain by SDS-PAGE

Haptoglobin

Human haptoglobin 1-1 (Hp1-1), the most efficient phenotype of the hemoglobin-binding glycoprotein, forms dimers through alfa1bèta-chain associations, enabling rapid neutralization of toxic free hemoglobin (Hb) with a binding capacity of 1.25–1.5 mg Hb per mg Hp. Its superior antioxidant capacity stems from compact polymer structures that enhance CD163 receptor-mediated clearance of Hb-Hp complexes by macrophages, suppressing iron-driven oxidative stress and NF-kappaB inflammatory pathways more effectively than Hp2-1 or Hp2-2 phenotypes. Clinically, Hp1-1 demonstrates protective effects against diabetic vascular complications by preserving endothelial nitric oxide bioavailability and reducing advanced glycation end-product formation, lowering retinopathy and nephropathy risks by 50–70% compared to other phenotypes. In sickle cell disease, Hp1-1 carriers exhibit 40% lower cell-free Hb levels during crises and a twofold reduction in multiorgan failure risk due to enhanced Hb sequestration. Paradoxically, Hp1-1 prevalence increases in cirrhosis (55% vs. 30% in healthy populations) as hepatic synthesis shifts toward acute-phase production despite systemic oxidative stress.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

-20C

41116100